potent selective nonpeptide agonist oxytocin receptor negligible affinity vasopressin contradictorily however though originally described selective oxytocin receptor lacking affinity vasopressin receptors since reported also act potent vasopressin receptor antagonist contrast oxytocin weak agonist shown cross barrier significantly greater extent exogenously applied oxytocin animal tests produces centrallymediated oxytocinergic actions anxiolytic effects antidepressant effect developed team ferring investigation potential clinical treatment anxiety disorders wyeth reached preclinical stage development development reported drug article relating genitourinary system stub help wikipedia expanding drug article relating nervous system stub help wikipedia expanding